Tunable nanotherapies to safely dissolve clots in stroke patients
Official title: Tunable multi-thrombolytic nanoformulations to treat complex clots with minimal hemorrhagic risk
Funded at University of Michigan at Dearborn · NIH-11444627 · Data updated 2026-11-12
A Nano-based therapy aims to deliver clot-busting drugs directly to the clot in ischemic stroke patients, potentially reducing bleeding risk.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Dearborn NIH-funded |
| Lab location | 1 site (Dearborn, United States) |
| Project start | August 1, 2026 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $567,166 |
| NIH project number | 1R15HL188412-01 |
| Project ID | NIH-11444627 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals at risk of ischemic stroke or those who have experienced an ischemic stroke and could benefit from safer thrombolytic therapy.
✕Less likely to help
Patients with non-ischemic stroke or those with conditions that contraindicate thrombolytic therapy may not benefit.
What this research studies
This NIH-funded project from the University of Michigan Dearborn explores tiny, tuneable nanoparticles that carry multiple clot-dissolving drugs straight to the clot. By targeting the clot site, the approach strives to improve effectiveness while lowering the risk of dangerous brain bleeding. The study combines plasmin and other agents with protective materials to enhance stability and bioavailability. Researchers will study how these nanoparticles behave in laboratory models and how they interact with brain cells and the blood–brain barrier. If successful, this work could lead to safer, more precise options for treating ischemic stroke.
Why it matters
Potential benefit: If successful, patients could have safer, more effective clot-dissolving treatment with lower risk of brain hemorrhage.
How similar studies have gone: Preclinical work shows promise for targeted thrombolysis with nanoparticles, but clinical effectiveness remains to be demonstrated.
Where this research is happening
-
University of Michigan at Dearborn
Dearborn, United States Active
Researchers
- Principal investigator: Kanapathipillai, Mathumai — University of Michigan at Dearborn
- Study coordinator: Kanapathipillai, Mathumai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.